Your binder contains too many pages, the maximum is 40.
We are unable to add this page to your binder, please try again later.
This page has been added to your binder.
April 14, 2016, Covington Alert
It has now been a full year since the Food and Drug Administration (“FDA”) approved the first biosimilar product to proceed under the new abbreviated biological pathway. With recent spotlights on the cost of pharmaceutical drug products, the potential of biosimilars to offer patients additional and more affordable choices has been widely discussed. Most recently, the Department of Health and Human Services’ 2017 Budget in Brief noted that the first approval under the abbreviated pathway could be the “next step to increasing treatment options for patients.” As the U.S. landscape continues to evolve, below are the top ten things to know about the reimbursement developments in the last year.
June 30, 2016
On June 23, the Centers for Medicare & Medicaid Services (“CMS”) published its final rule to implement Medicare laboratory policy changes made under Section 216(a) of the Protecting Access to Medicare Act of 2014 (“PAMA”). Responding to public comments it received on last year’s proposed rule, CMS made a number of significant changes and postponed the PAMA ...
2016, American Health Lawyers Association
October 7, 2015, Covington Alert